Progenics Pharmaceuticals, Inc. (PGNX) Announces The Appointment Of Karen Ferrante, M.D. To Its Board Of Directors
1/30/2014 8:55:55 AM
TARRYTOWN, N.Y., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company focused on the development of innovative approaches to targeting and treating cancer, announced today that Karen Ferrante, M.D., a healthcare industry leader with more than two decades of experience in the areas of oncology and clinical research and development, has been elected to its Board of Directors. Most recently Dr. Ferrante held the positions of Chief Medical Officer and was a Head of R & D at Millennium, The Takeda Oncology Company, and Oncology Therapeutic Area Head at Takeda Pharmaceutical Company.
Help employers find you! Check out all the jobs and post your resume.
comments powered by